CVE:AQS

Aequus Pharmaceuticals - AQS Stock Forecast, Price & News

C$0.03

-0.01 (-25.00%)

(As of 03/16/2023)

Add

Compare

Today's Range: C$0.03
▼
C$0.03
50-Day Range: C$0.03
▼
C$0.05
52-Week Range: C$0.02
▼
C$0.10

Volume: 10,000 shs
Average Volume: 155,214 shs
Market Capitalization: C$3.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Aequus Pharmaceuticals (CVE:AQS) Stock

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Stock News Headlines

December 20, 2022 | finance.yahoo.com

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

November 30, 2022 | finanznachrichten.de

Aequus Pharmaceuticals: Aequus Reports Third Quarter 2022 Financial Highlights

March 21, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

November 30, 2022 | finance.yahoo.com

Aequus Reports Third Quarter 2022 Financial Highlights

November 29, 2022 | finance.yahoo.com

Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)

October 9, 2022 | reuters.com

Aequus Pharmaceuticals Inc

August 30, 2022 | seekingalpha.com

Aequus Pharmaceuticals reports Q2 results

August 29, 2022 | finance.yahoo.com

Aequus Reports Second Quarter 2022 Financial Highlights and General Update

March 21, 2023 | Weiss Ratings (Ad)

Urgent Warning

July 13, 2022 | finance.yahoo.com

IIROC Trading Resumption - AQS

July 13, 2022 | finance.yahoo.com

Aequus Resumes Trading on TSX Venture Exchange

May 2, 2022 | finance.yahoo.com

IIROC Trading Halt - AQS.WT

May 2, 2022 | finance.yahoo.com

IIROC Trading Halt - AQS.DB

April 22, 2022 | benzinga.com

Aequus Announces Director Resignation

January 11, 2022 | finance.yahoo.com

Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada

January 6, 2022 | finance.yahoo.com

Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

November 5, 2021 | ca.finance.yahoo.com

Is Aequus Pharmaceuticals (CVE:AQS) Weighed On By Its Debt Load?

August 25, 2021 | finance.yahoo.com

Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise

July 5, 2021 | finance.yahoo.com

AEQUUS PHARMACEUTICALS INC (AQS.V) stock forecast and price target

June 9, 2021 | proactiveinvestors.com

Aequus Pharmaceuticals says it will maintain commercial relationship with Sandoz into 2022

June 9, 2021 | ca.finance.yahoo.com

Aequus Provides Commercial Update

May 31, 2021 | markets.businessinsider.com

Aequus Provides General Update and First Quarter 2021 Financial Highlights

April 23, 2021 | benzinga.com

Aequus Provides General Update and Reports Record 2020 Financial Results

April 19, 2021 | markets.businessinsider.com

Aequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference

April 6, 2021 | proactiveinvestors.com

Aequus Pharmaceuticals receives $1.48 million from warrant acceleration exercises

April 6, 2021 | finance.yahoo.com

Aequus Provides update on Warrant Acceleration

March 1, 2021 | proactiveinvestors.com

Aequus Pharmaceuticals announces the commercial availability of Evolve preservative-free lubricating eye drops for dry eye care

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Company Calendar

Today: 3/20/2023
Next Earnings (Estimated): 3/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: CVE
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: CVE:AQS
CUSIP: N/A
CIK: N/A
Web: www.aequuspharma.ca
Phone: +1-604-3367906
Fax: N/A
Employees: 10
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C($0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-2,520,000.00
Net Margins: -135.60%
Pretax Margin: N/A
Return on Equity: -291.74%
Return on Assets: -41.77%

Debt

Debt-to-Equity Ratio: 138.88
Current Ratio: 0.54
Quick Ratio: 0.46

Sales & Book Value

Annual Sales: C$1.86 million
Price / Sales: 2.14
Cash Flow: C$0.01 per share
Price / Cash Flow: 5.00
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 132,630,000
Free Float: N/A
Market Cap: C$3.98 million
Optionable: Not Optionable
Beta: 0.49

Key Executives

Mr. Douglas Glen Janzen (Age 54)
Chairman, CEO & Pres
Comp: $225k

Ms. Ann Fehr CGA (Age 54)
CPA, CFO & Corp. Sec.
Comp: $155.94k

Mr. Stuart Fowler
Strategic Commercial Advisor & Independent Director

Mr. Grant Larsen
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

AQS Stock - Frequently Asked Questions

How have AQS shares performed in 2023?: Aequus Pharmaceuticals' stock was trading at C$0.04 at the beginning of 2023. Since then, AQS stock has decreased by 14.3% and is now trading at C$0.03.
View the best growth stocks for 2023 here.
When is Aequus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our AQS earnings forecast.
What other stocks do shareholders of Aequus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle (CCI), Charlotte's Web (CWBHF), (FIRE.V) (FIRE), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Planet 13 (PLNHF).
What is Aequus Pharmaceuticals' stock symbol?: Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS."

How do I buy shares of Aequus Pharmaceuticals?: Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Aequus Pharmaceuticals' stock price today?: One share of AQS stock can currently be purchased for approximately C$0.03.
How much money does Aequus Pharmaceuticals make?: Aequus Pharmaceuticals (CVE:AQS) has a market capitalization of C$3.98 million and generates C$1.86 million in revenue each year. The company earns C$-2,520,000.00 in net income (profit) each year or C($0.01) on an earnings per share basis.
How can I contact Aequus Pharmaceuticals?: Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The official website for the company is www.aequuspharma.ca. The company can be reached via phone at +1-604-3367906.

This page (CVE:AQS) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial